

About DoseMe

DoseMe has developed the world's first precision dosing platform - DoseMeRx - designed for clinicians at the point-of-care. Using readily available patient data, it provides real-time dose-related decision support. From just one blood sample, DoseMeRx virtually constructs a model of each patient's individual pharmacokinetics, allowing clinicians to predict the optimal dose of medication - taking away the guess work and manual calculations.



Impact

DoseMe has made considerable commercial progress throughout their participation in the ANDHealth+ program. They successfully expanded their operations in both Australia and the US and entered new markets in the US, as well as South Africa, United Kingdom, Portugal, Brazil, Slovenia and Italy. The DoseMe team grew significantly, creating seven new jobs.

The DoseMeRx platform was ranked in the top 20 2018 Hot Apps for healthcare providers by Health Data Management. They also developed and validated a SMART-on-FHIR application available in both Cerner and Epic app stores.

Testimonial



"The ANDHealth process is unique, as unlike many accelerators and grants which focus on very early stage ideas, ANDHealth supports innovative companies like DoseMe to expand into other marketplaces and sustain that growth. Developing a strategy for DoseMe in partnership with a talented set of ANDHealth advisors, with expertise ranging from clinical research through to pharmaceutical marketing, is of distinct value as we continue to scale our operations."

Charles Cornish, Chief Executive Officer, DoseMe


DoseMe Milestones

Milestones	Before ANDHealth+ 2017 Program	After ANDHealth+ 2017 Program
US Market Entry Strategy		
Target Market Strategy		
Protection of Design Assets		
Partnerships Formed		
Investment Readiness		• • • • •





Opportunities Delivered by ANDHealth



DoseMe and ANDHealth

DoseMe was selected from over 50 companies to be part the ANDHealth+ 2017 program. The ANDHealth+ program assists Australian mid-stage digital health companies to meet key investor, partner and customer requirements around clinical and commercial validation. ANDHealth+ requires no equity consideration, provides the company with a bespoke advisory panel, ANDHealth, contributes A\$60,000 to securing relevant third-party expertise and cohort companies also benefit from over \$150,000 worth of in-kind offerings, including technical platform services, media & communications, insurance, human resources, intellectual property and legal support.

